THIRD QUARTER 2025 HIGHLIGHTS 1 SAFE HARBOR STATEMENT Forward Looking Statements This presentation, as well as other written or oral communications made from time to time by us, may contain certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements refer to our current expectations and projections relating to our financial condition, results of operations, plans, objectives, strategies, future performance, and business. All sta ...

Safe harbor & Non-gaap measures Forward-Looking Statements This presentation contains statements by Celsius Holdings, Inc. ("Celsius Holdings", "we", "us", "our" or the "Company") that are not historical facts and are considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may address, among other things, our prospects, plans, business strategy and expected financial and operational results. You can identify these sta ...

Second Quarter Fiscal 2026 Results November 6, 2025 © 2025 Haemonetics Corporation Q2 Fiscal 2026 Conference Call Detail Conference call will take place at 8:00 a.m. ET on November 6, 2025, and can be accessed via live webcast: Link or teleconference: Link The financial release, accompanying slides, and a replay of the conference call (beginning at 11:00 AM ET) are available online at www.haemonetics.com. Conference call speakers: Chris Simon President & CEO James D'Arecca EVP, Chief Financial Officer Olga ...

Financial Performance - Revenue for Q3 2025 was $20.6 million, at the high end of the $19-$21 million guidance range[7, 8] - Gross margin for Q3 2025 was 58.4%, exceeding the guidance range of 56%-58%[7, 8] - Adjusted EBITDA for Q3 2025 was $2.0 million, compared to $1.3 million in Q3 2024[7, 8] - Cash provided by operations was $6.8 million, up from ($0.3 million) in the same period last year[7] Regional Performance - APAC revenue decreased by 19.6% year-over-year, impacted by China tariffs[9] - EMEA revenue was relatively flat, down 0.6% year-over-year, influenced by macroeconomic instability[9] - Americas revenue decreased by 4.4% year-over-year, with a recovery in Pre-Clinical driven by NIH/ACA funding[9] Outlook and Strategy - The company is focused on refinancing or repaying the existing credit agreement in Q4 2025[7] - Q4 revenue is projected to range from $22.5 million to $24.5 million[17] - Q4 gross margin is expected to range from 58% to 60%[17]

Q3 2025 Financial Performance - Revenue increased to $684 million in Q3 2025 compared to $708 million in Q3 2024[42] - Adjusted EBITDA increased by 32% to $125 million in Q3 2025 from $95 million in Q3 2024[13, 43] - Recurring revenue increased by 5% to $425 million in Q3 2025 from $405 million in Q3 2024[13] - Non-GAAP Diluted EPS was $031 in Q3 2025, compared to $001 in Q3 2024[13, 45] YTD 2025 Financial Performance - Recurring revenue increased by 4% to $1254 million YTD 2025 from $1211 million YTD 2024[26] - Adjusted EBITDA increased by 20% to $295 million YTD 2025 from $237 million YTD 2024[26] Debt and Cash Flow - Total debt as of September 30, 2025, was $1105 million[18] - Net debt was $823 million as of September 30, 2025[18, 48] - Adjusted Net Leverage Ratio is 20x, calculated as net debt divided by the last twelve months Adjusted EBITDA[18, 48] FY 2025 Outlook - Total revenue is projected to be between $2650 million and $2670 million[20] - Adjusted EBITDA is projected to be between $420 million and $435 million[20]

Third Quarter 2025 Financial Results and Recent Corporate Updates November 2025 Forward-Looking Statements This presentation contains forward-looking statements, including statements relating to our strategy and plans; potential of and expectations for our business, commercial products, and pipeline programs; our goals, objectives, and priorities and our expectations under our growth strategy (including our expectations regarding our commercial products and launches, clinical stage products, revenue growth ...

Q3 2025 Performance Highlights - Implemented Providers increased by 13.1% compared to Q3 2024[8, 18] - Practice Collections grew by 27.1% compared to Q3 2024[8, 18] - Adjusted EBITDA increased by 61.6% compared to Q3 2024, reaching a 30.5% margin, a 720 bps increase[8] Year-to-Date (YTD) 2025 Performance - Platform Contribution increased by 26.2%[21] - Care Margin increased by 19.6%[21] - Adjusted EBITDA increased by 43.5%[21] Value-Based Care (VBC) Performance - Total shared savings of $234.1 million (+32.6%) across Privia ACOs in MSSP 2024 performance year[15] - Mid-Atlantic ACO achieved the highest savings rate (11.0%) among ACOs with 40K+ lives for the 5th consecutive year[15] Financial Position and Outlook - Pro forma net cash of $409.9 million as of September 30, 2025[26] - Expects to use $100 million in Q4 2025 to acquire Evolent's ACO business[8, 26] - Updated FY'25 guidance for Practice Collections is $3.45 billion - $3.5 billion[27] - Updated FY'25 guidance for GAAP Revenue is $2.05 billion - $2.1 billion[27] - Updated FY'25 guidance for Adjusted EBITDA is $118 million - $121 million[27]

Financial Performance - Lantheus reported revenues of $384 million for Q3 2025, a 1.4% increase year-over-year[13, 35] - Adjusted EPS for Q3 2025 was $1.27, a 25.3% decrease year-over-year[13, 35] - Radiopharmaceutical Oncology sales were $240.6 million, a 7.4% decrease year-over-year, while U S volumes grew by 3 3%[35, 19] - Precision Diagnostics sales were $129.7 million, a 25 0% increase year-over-year, driven by DEFINITY sales growth of 6 3% and the addition of Neuraceq[35, 21] - Strategic Partnerships sales were $13.7 million, a 10.1% decrease year-over-year[35] Strategic Initiatives and Pipeline - Lantheus completed the acquisition of Life Molecular Imaging and repurchased $100 million of stock during the quarter[39] - The company anticipates four key product approvals by year-end 2026, including a new PSMA PET imaging agent, MK-6240, LNTH-2501, and PNT2003[15, 46] - Lantheus is expanding geographic coverage for Alzheimer's disease imaging, aiming for broad access across leading centers and community practices[25] - The company is advancing MK-6240, a F18 PET imaging agent for detecting tau in adults being evaluated for Alzheimer's disease, with a PDUFA date of August 13, 2026[29, 31] Financial Guidance - Lantheus updated its FY 2025 revenue guidance to $1.49 billion-$1.51 billion[42] - The company updated its FY 2025 adjusted fully diluted EPS guidance to $5.50-$5.65[42]

Q3 2025 Investor Presentation Forward-Looking Statements Certain statements in this presentation are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, in ...

Q2 2026 Financial Highlights - Revenue reached $319.0 million, a 15% year-over-year increase[10] - Gross Payment Volume (GPV) grew by 22% year-over-year to $10.8 billion[10] - GPV accounted for 43% of Gross Transaction Volume (GTV)[10] - Gross Transaction Volume (GTV) amounted to $25.3 billion[10] - Recurring subscription and transaction-based revenue represented approximately 97% of total revenue[10] - Average Revenue Per User (ARPU) increased by 15% to approximately $685[10] Financial Outlook - Q3 2026 revenue is projected to be approximately $309 - $312 million[15] - At least 15% year-over-year gross profit growth is expected for Q3 2026[15] - Adjusted EBITDA for Q3 2026 is anticipated to be approximately $18 - $20 million[15] - Fiscal Year 2026 is expected to have at least 12% revenue growth year-over-year[15] - Fiscal Year 2026 is expected to have at least 15% gross profit growth year-over-year[15] - Adjusted EBITDA for Fiscal Year 2026 is projected to be at least $70 million[15]